Moran Wealth Management LLC Buys 21,334 Shares of Fresenius Medical Care AG (NYSE:FMS)

Moran Wealth Management LLC lifted its stake in shares of Fresenius Medical Care AG (NYSE:FMS - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 254,710 shares of the company's stock after acquiring an additional 21,334 shares during the quarter. Moran Wealth Management LLC's holdings in Fresenius Medical Care were worth $5,767,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in FMS. ABC Arbitrage SA bought a new position in shares of Fresenius Medical Care in the fourth quarter worth approximately $4,215,000. Quantinno Capital Management LP raised its holdings in Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company's stock valued at $2,345,000 after acquiring an additional 48,554 shares during the period. Franklin Resources Inc. lifted its position in shares of Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company's stock valued at $1,490,000 after acquiring an additional 2,386 shares in the last quarter. QRG Capital Management Inc. boosted its stake in shares of Fresenius Medical Care by 16.7% in the fourth quarter. QRG Capital Management Inc. now owns 67,973 shares of the company's stock worth $1,539,000 after acquiring an additional 9,706 shares during the period. Finally, Crossmark Global Holdings Inc. grew its position in shares of Fresenius Medical Care by 2.2% during the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company's stock worth $1,456,000 after purchasing an additional 1,398 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on FMS. Bank of America raised shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. StockNews.com upgraded Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Truist Financial boosted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a research report on Monday, January 6th.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS traded up $0.87 on Friday, reaching $24.04. The company's stock had a trading volume of 303,252 shares, compared to its average volume of 315,456. The company has a 50-day simple moving average of $23.63 and a 200 day simple moving average of $22.14. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a market cap of $14.10 billion, a P/E ratio of 19.86, a PEG ratio of 0.76 and a beta of 0.99. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $25.25.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.